This inventor holds 3 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Oxthera Intellectual Property Ab, Oxthera Intellectual Property. Active years: 2018-2021.
Company Filing History:
Years Active: 2018-2021
Title: Elisabeth Lindner: Innovator in Oxalate-Related Treatments
Introduction
Elisabeth Lindner is a prominent inventor based in Stockholm, Sweden. She has made significant contributions to the field of medical treatments related to oxalate-related disorders. With a total of 3 patents to her name, her work focuses on innovative solutions for managing oxalate imbalances in patients.
Latest Patents
One of her latest patents is titled "Secretagogues derived from oxalobacter formigenes." This invention relates to a secretagogue compound derived from oxalate-degrading bacteria, aimed at treating oxalate-related diseases. The administration of this secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. Additionally, she has developed a patent for "Compositions and methods for the treatment or prevention of oxalate-related disorders." This disclosure pertains to pharmaceutical compositions and methods for treating and preventing oxalate-related disorders, particularly suitable for late-stage hyperoxaluria characterized by high plasma-oxalate levels and a decrease in kidney function.
Career Highlights
Elisabeth has worked with notable companies such as Oxthera Intellectual Property AB and Oxthera Intellectual Property. Her innovative work has positioned her as a key figure in the development of treatments for oxalate-related conditions.
Collaborations
Throughout her career, Elisabeth has collaborated with professionals like Maria Åkerman and Helena Cowley. These partnerships have contributed to her success in the field of medical innovation.
Conclusion
Elisabeth Lindner's contributions to the treatment of oxalate-related disorders highlight her role as a significant inventor in the medical field. Her innovative patents and collaborations demonstrate her commitment to improving patient outcomes through scientific advancements.